IGF-1 DES vs Testosterone
Limited Research vs FDA Approved
synergistic Researched · 95% Testosterone increases IGF-1 receptor density and satellite cell number, amplifying the local effects of IGF-1 DES at the injection site.
Molecular Data
IGF-1 DES Testosterone
Weight ~7,000 Da 288.42 Da (base)
Half-life 20-30 minutes ~8 days (cypionate)
Chain 67 amino acids —
Type Truncated IGF-1 analog Steroid hormone (C19H28O2)
Key Benefits
IGF-1 DES
01 Approximately 10x more potent than native IGF-1
02 100% bioactive -- does not bind to IGF binding proteins
03 Extremely short half-life enables localized, site-specific action
04 Promotes satellite cell activation for muscle hyperplasia
05 Minimal systemic exposure compared to IGF-1 LR3
Testosterone
01 Restoration of normal testosterone levels in hypogonadal men
02 Increased lean muscle mass and strength
03 Improved bone mineral density and reduced fracture risk
04 Enhanced libido, sexual function, and erectile quality
05 Improved mood, energy, motivation, and cognitive clarity
06 Reduction in body fat percentage, particularly visceral fat
07 Increased red blood cell production and oxygen-carrying capacity
08 Improved insulin sensitivity and metabolic health markers
Dosing Protocols
IGF-1 DES
20-50mcg post-workout (site-specific IM injection) / Post-workout only, injected into trained muscle
Beginner Protocol 20-30mcg Post-workout, injected into trained muscle
Intermediate 30-50mcg Post-workout, injected into trained muscle
Advanced 50mcg Post-workout, split across multiple trained muscles
Testosterone
100-200 mg/week (TRT) / 1-2x per week (injectable)
TRT - Standard Replacement 100-200 mg/week 1-2x per week
TRT - Conservative Start 80-100 mg/week 2x per week (40-50 mg per injection)
TRT - Propionate Protocol 25-50 mg every other day Every other day or 3x per week
Performance Enhancement - Moderate 300-500 mg/week 2x per week
Performance Enhancement - Advanced 500-750 mg/week 2-3x per week
Side Effects
IGF-1 DES
Hypoglycemia -- consume carbohydrates after injection
Localized swelling and soreness at injection site
Increased pump in targeted muscles
Mild lightheadedness shortly after injection
Testosterone
Acne and oily skin (increased sebum production via DHT)
Water retention and bloating (estrogen-mediated)
Mild mood changes (irritability, increased assertiveness)
Increased hematocrit and hemoglobin (erythrocytosis)
Testicular atrophy (suppression of LH/FSH from exogenous testosterone)
Injection site pain, redness, or irritation
Increased body hair growth
Mild elevation in blood pressure
Contraindications
Not approved for human use -- research chemical only
Cancer history or active malignancy (IGF-1 promotes cell proliferation)
Diabetes or impaired glucose regulation
WADA prohibited substance -- causes failed drug tests
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled severe heart failure
Untreated severe obstructive sleep apnea
Desire for near-term fertility (without concurrent HCG/FSH)
Pregnancy or potential exposure to pregnant women (Category X)
Hypersensitivity to testosterone or any formulation components
Research Evidence
IGF-1 DES Testosterone
Status Limited Research FDA Approved
References 4 studies 5 studies
Latest — June 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.